MedTrace Logo

Randomized Phase III Study of Intensive Chemotherapy With or Without Dasatinib (Sprycel™)

NCT02013648 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 204

Last updated 2024-02-23

No results posted yet for this study

Summary

This is a randomized phase III open-label, multicenter trial evaluating standard induction therapy (daunorubicin \[DNR\] and cytarabine \[Ara-C\]) and consolidation therapy (high-dose cytarabine \[HDAC\]) with or without dasatinib in adult patients with newly diagnosed CBF-AML

Conditions

  • Acute Myeloid Leukemia (AML)

Interventions

DRUG

Dasatinib

DRUG

Cytarabine

DRUG

Daunorubicin

DRUG

Idarubicin

Sponsors & Collaborators

  • University of Ulm

    lead OTHER

Principal Investigators

  • Hartmut Doehner, Prof. Dr. · University of Ulm

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-07-31
Primary Completion
2024-02-29
Completion
2024-02-29

Countries

  • Austria
  • Germany

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02013648 on ClinicalTrials.gov